Arrowhead announces FDA approval of Redemplo for FCS

Arrowhead (ARWR) Pharmaceuticals announced that the U.S. Food and Drug Administration has approved Redemplo, a small interfering RNA medicine, as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome. “Redemplo is the first and only FDA-approved siRNA medicine for people living with FCS and can be self-administered at home with a simple subcutaneous injection once every three months. Redemplo utilizes the proprietary and differentiated Targeted RNAi Molecule platform and is Arrowhead’s first FDA-approved medicine, marking a major milestone for the company as it transitions into commercial-stage,” the company stated. Redemplo will be available in the U.S. before the end of the year, the company added.